Moonwalk Biosciences Stock

www.moonwalk.bioHealthcare / BioTech & PharmaFounded: 2022

Moonwalk Biosciences, founded in 2022 by biochemist Feng Zhang and Alex Aravanis, former chief technology officer at biotechnology company Illumina, is an epigenetics company. With a focus on early-stage therapeutics, the team strives to develop new approaches for epigenetic engineering by looking at the genome holistically as well as at the single-cell resolution level. The company aims to differentiate itself by pairing its epigenetic discovery platform with precise targeting so providers can tap into the entire epigenome. Moonwalk Biosciences is headquartered in San Francisco, California.

Register To Buy and Sell Shares

For more details on financing and valuation for Moonwalk Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Moonwalk Biosciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Moonwalk Biosciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Arash Jamshidi Ph.D
Co-Founder, Chief Technology Officer & President
Justin Valley Ph.D
Co-Founder & Chief Operating Officer
Elaine Cheung
Chief Business Officer
Alexander Aravanis Ph.D
Co-Founder & Chief Executive Officer

Frequently Asked Questions About Moonwalk Biosciences’ Stock

plusminus
Can you buy Moonwalk Biosciences’ stock?
Moonwalk Biosciences is not publicly traded on NYSE or NASDAQ in the U.S. To buy Moonwalk Biosciences’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Moonwalk Biosciences’ stock?
Yes, you can sell stock of a private company like Moonwalk Biosciences. Forge can help you sell your Moonwalk Biosciences stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Moonwalk Biosciences’ stock price?
Moonwalk Biosciences is a privately held company and therefore does not have a public stock price. However, you may access Moonwalk Biosciences’ private market stock price with Forge Data.
plusminus
What is Moonwalk Biosciences’ stock ticker symbol?
Moonwalk Biosciences does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Moonwalk Bio Grabs $57 Million, Joins Push for ‘Epigenetic’ Treatments
Biotechnology startup Moonwalk Biosciences has raised $57 million in venture capital and joined a push to treat diseases through drugs that activate or suppress genes. Proponents say this new twist on genetic medicine, “epigenetic editing,” promises to lead to treatments or cures for a variety of common medical scourges, such as cancer and chronic hepatitis B.
Updated on: Feb 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.